Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma
1998

Intraperitoneal and Intravenous Chemotherapy for Colon Cancer

Sample size: 241 publication Evidence: moderate

Author Information

Author(s): W Scheithauer, GV Kornek, A Marczell, J Karner, G Salem, R Greiner, D Burger, F StogeP, J Ritschel, E Kovats, HM Vischer, B Schneeweiss, D Depisch

Primary Institution: University of Vienna

Hypothesis

Does combined intraperitoneal and intravenous chemotherapy yield better results than conventional therapy for resected colon cancer?

Conclusion

Combined intraperitoneal and intravenous chemotherapy with fluorouracil and leucovorin is a promising treatment strategy that reduces recurrence and improves survival in patients with resected stage III colon cancer.

Supporting Evidence

  • Patients receiving the investigational arm had a 43% reduction in mortality rate.
  • Combined treatment showed a significant improvement in disease-free survival.
  • Adverse reactions were generally mild and less frequent in the investigational arm.

Takeaway

This study tested a new way to give chemotherapy for colon cancer and found that it helps patients live longer and have fewer relapses.

Methodology

Patients were randomly assigned to receive either standard therapy with fluorouracil and levamisole or a combination of fluorouracil and leucovorin administered both intravenously and intraperitoneally.

Limitations

The follow-up duration was limited, and the sample size for stage II patients was too small to draw definitive conclusions.

Participant Demographics

Patients had resected stage II or III colon cancer, with a median age of 63 years.

Statistical Information

P-Value

P=0.0005

Confidence Interval

95% confidence interval 26-70%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication